Home » Vivitrol to Receive Priority Review From FDA
Vivitrol to Receive Priority Review From FDA
Alkermes Tuesday announced that the supplemental New Drug Application for Vivitrol (naltrexone for extended-release injectable suspension) for opioid dependence has been designated a priority review by the FDA.
The Street
The Street
Upcoming Events
-
07May
-
14May
-
30May